The FDA database lists a supplement, recorded on 24 October 2026, to the new drug application for OZURDEX, the dexamethasone intravitreal implant held by AbbVie. No indication, safety change or reason is given in the record. Supplements of this kind are often administrative, covering labelling, manufacturing or packaging.
This is the only regulatory record in the respiratory sweep today, and its direct relevance to pulmonary practice is limited. It is an eye implant used for macular oedema and uveitis, not a respiratory product.
The one practical overlap is steroid exposure. Patients with chronic lung disease often receive repeated systemic and inhaled steroids, and an intravitreal implant adds to the picture an ophthalmologist and a pulmonologist each see only in part.
- Treat this as an administrative licence change unless FDA publishes details
- Record intravitreal steroid implants in the medication history of patients with lung disease
- Remember cumulative steroid exposure when assessing cataract, glaucoma and glucose risk
Why it matters
It changes nothing for pulmonologists beyond a reminder to record every source of steroid exposure.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free